Is Mounjaro Being Approved for Weight Loss?

Last reviewed: July 13, 2026

Last updated: July 13, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, the active ingredient in Mounjaro, has demonstrated weight loss efficacy in clinical trials, yet the FDA has not granted a separate weight loss indication for this dual GLP-1/GIP receptor agonist. PlexusDx provides access to compounded tirzepatide from licensed 503A pharmacies, offering patients a practical path to personalized peptide therapy without waiting for additional regulatory approvals.

Tirzepatide FDA Approval Status for Weight Management

The FDA approved tirzepatide under the brand name Mounjaro in 2022 exclusively for type 2 diabetes management. While robust clinical data supports tirzepatide's weight loss potential—with patients in trials losing up to 22% of body weight—the agency has not yet issued a separate weight loss indication like it did for semaglutide (Wegovy). This distinction matters for insurance coverage and manufacturer labeling, but does not reflect the medication's clinical effectiveness for weight reduction.

Off-label prescribing of tirzepatide for weight loss is legal and increasingly common among providers who specialize in metabolic health. The SURPASS-4 trial showed that tirzepatide outperformed semaglutide for weight reduction in participants with obesity, making it an evidence-backed option. PlexusDx works with licensed compounding pharmacies to make tirzepatide accessible regardless of approval status, ensuring patients can access this dual-peptide therapy based on clinical need rather than regulatory timelines.

How Tirzepatide Works Differently Than Other GLP-1 Options

Tirzepatide activates two separate hormone pathways: GLP-1 and GIP receptors, while semaglutide targets only GLP-1. This dual mechanism may explain why tirzepatide produced greater weight loss in head-to-head trials and offers a distinct therapeutic approach. The dual-receptor activation affects appetite, blood sugar control, and metabolic rate through complementary biological pathways that single-agent therapies cannot replicate.

PlexusDx's Precision Peptide Genetic Test identifies how your individual genetic variants in the GLP1R and GIPR genes influence your response to dual-compound therapy. Understanding your genetic predispositions helps PlexusDx clinicians personalize your tirzepatide dose and protocol, ensuring the therapy aligns with your unique peptide pathway function. This genetic insight is not available through standard prescribing and represents a key advancement in precision weight loss medicine.

PlexusDx Tirzepatide Injection: Pricing and Accessibility

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) with a flat-rate pricing model—your dose may need to go up, but your price won't. This fixed cost covers all three commitment tiers and eliminates the flat per-compound pricing escalation seen elsewhere. HSA and FSA funds are accepted, and PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization delays.

Each tirzepatide prescription is compounded by licensed 503A pharmacies meeting rigorous pharmaceutical standards. PlexusDx also offers oral tirzepatide at $349/mo (or $279/mo on the 6-month plan) for patients preferring tablet administration, plus the GLP-Squared dual-compound injection combining semaglutide and tirzepatide for $289 monthly if you want maximum peptide pathway coverage. The Precision Peptide Genetic Test ($99 add-on after your first treatment month) further optimizes your therapy by revealing the pathway-level variants involved across 14 metabolic pathways.

Clinical Evidence Behind Tirzepatide Weight Loss Efficacy

The SURPASS trial program enrolled over 4,600 adults with obesity or overweight with comorbidities. Participants receiving tirzepatide 15 mg weekly lost an average of 22.5% of baseline body weight over 72 weeks, compared to 16.1% with semaglutide 2.4 mg—a clinically meaningful difference. These results, published in major medical journals, demonstrate tirzepatide's role in modern weight management even before a formal weight loss indication exists.

Beyond weight loss, tirzepatide improved cardiometabolic markers including blood pressure, cholesterol, and inflammatory markers in trial participants. These broader health benefits reflect the medication's mechanism of action across multiple metabolic systems. PlexusDx clinicians review this evidence when determining whether tirzepatide aligns with your health goals and baseline metabolic profile.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide FDA-approved for weight loss right now?

Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) but does not yet carry an official weight loss indication. However, off-label use for weight management is legal and supported by clinical evidence. PlexusDx provides access to compounded tirzepatide through licensed 503A pharmacies, offering you a pathway to this therapy today regardless of approval status.

Does tirzepatide work better than semaglutide for weight loss?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, and GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How much does PlexusDx compounded tirzepatide cost monthly?

PlexusDx tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) on a flat-rate pricing model across all three commitment tiers. Your dose can increase without raising your monthly cost. HSA and FSA are accepted, and the service covers all 50 states with no insurance requirement or membership fee.

Are PlexusDx compounded medications safe and regulated?

All PlexusDx tirzepatide is compounded by licensed 503A compounding pharmacies operating under strict FDA oversight and USP standards. These facilities must meet rigorous quality, sterility, and potency requirements. While compounded medications are not FDA-approved as brand-name products, 503A pharmacy compounding is a legal, regulated practice used throughout healthcare.

How does the Precision Peptide Genetic Test help with tirzepatide therapy?

The test ($99 add-on after your first month) analyzes 150+ genetic insights across 14 metabolic pathways, including key variants in GLP1R, GIPR, FTO, and MC4R genes. These variants influence how your body responds to dual-compound tirzepatide therapy and help PlexusDx clinicians tailor your dose and protocol for maximum efficacy and tolerability based on your genetic predispositions.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Weight Loss Injections Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.